Huier Kangxin, a full-dose non-adjuvant vaccine by Jiangsu Ab&B Bio-Tech Co Ltd, has become the first tetravalent influenza virus subunit vaccine to receive approval for sale in China by the National Medical Products Administration.
Huier Kangxin is said to be purer, have fewer side effects, and more comprehensive protection compared to similar vaccines. The clinical trial results, which indicate that Huier Kangxin is a safe and effective influenza vaccine that provides broader and sufficient protection against seasonal influenza viruses, have been published in the Vaccine journal.
An exterior view of Jiangsu Ab&B Bio-Tech Co Ltd. [Photo/cmc.gov.cn]
Located in the Taizhou Medical High-tech Zone in Taizhou, East China's Jiangsu province, Jiangsu Ab&B Bio-Tech Co Ltd focuses on the research and development, registration application, production and sales of innovative vaccines for human use.
The company has in recent years increased its spending on R&D and developed multiple vaccine lines including viral vaccines, bacterial vaccines, conjugate vaccines and recombinant subunit vaccines.